GSK's Arexvy and Pfizer's shot Abrysvo, both protein-based vaccines, are also approved in Canada for adults aged 60 years and ...

It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Pfizer showcased new treatments for atopic dermatitis, the leading type of eczema, at the 7th China International Import Expo ...

Pfizer (PFE, Financials) announced plans to invest $1 billion in China over the next five years to enhance research and ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Pfizer's non-COVID product revenues surged 14% operationally last quarter. The oncology business delivered exceptional ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.